Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Intratumoral SD-101 (Toll-Like Receptor 9 Agonist), Nivolumab, and Radiotherapy for Treatment of Chemotherapy-Refractory Metastatic Pancreatic Adenocarcinoma

NCT04050085 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.

NCT NCT04050085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04050085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Intratumoral SD-101 (Toll-Like Receptor 9 Agonist), Nivolumab, and Radiotherapy for Treatment of Chemotherapy-Refractory Metastatic Pancreatic Adenocarcinoma
Lead sponsor
University of California, Davis
Phase
Phase 1
Overall status
Completed
Start date
August 15, 2019
Completion date
May 14, 2022
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic adenocarcinoma, refractory pancreatic adenocarcinoma, stage iv pancreatic cancer ajcc v8